| Title | Prediction and longitudinal study of CSF biomarkers in mild cognitive impairment. |
| Publication Type | Journal Article |
| Year of Publication | 2009 |
| Authors | Brys M, Pirraglia E, Rich K, Rolstad S, Mosconi L, Switalski R, Glodzik-Sobanska L, de Santi S, Zinkowski R, Mehta P, Pratico D, Louis LASaint, Wallin A, Blennow K, de Leon MJ |
| Journal | Neurobiol Aging |
| Volume | 30 |
| Issue | 5 |
| Pagination | 682-90 |
| Date Published | 2009 May |
| ISSN | 1558-1497 |
| Keywords | Aged, Aged, 80 and over, Alzheimer Disease, Amyloid beta-Peptides, Biomarkers, Cognition Disorders, Cohort Studies, Disease Progression, Early Diagnosis, Female, Humans, Isoprostanes, Longitudinal Studies, Male, Middle Aged, Peptide Fragments, Predictive Value of Tests, Prognosis, tau Proteins |
| Abstract | OBJECTIVES: To longitudinally evaluate five cerebrospinal fluid (CSF) biomarkers in the transition from mild cognitive impairment (MCI) to Alzheimer's disease (AD). METHODS: A baseline and 2-year follow-up clinical and CSF study of 86 subjects, including 22 MCI patients that declined to AD (MCI-AD), 43 MCI that did not deteriorate (MCI-MCI) and 21 controls (NL-NL). All subjects were studied for total and phosphorylated tau (T-tau, P-tau(231)), amyloid beta (Abeta) Abeta(42)/Abeta(40) ratio, isoprostane (IP) as well as P-tau(231)/Abeta(42/40) and T-tau/Abeta(42/40) ratios. RESULTS: At baseline and at follow-up MCI-AD showed higher levels P-tau(231), T-tau, IP, P-tau(231)/Abeta(42/40) and T-tau/Abeta(42/40) ratios and lower Abeta(42)/Abeta(40) than MCI-MCI or NL-NL. Baseline P-tau(231) best predicted MCI-AD (80%, p<0.001) followed in accuracy by P-tau(231)/Abeta(42/40) and T-tau/Abeta(42/40) ratios (both 75%, p's<0.001), T-tau (74%, p<0.001), Abeta(42)/Abeta(40) (69%, p<0.01), and IP (68%, p<0.01). Only IP showed longitudinal effects (p<0.05). CONCLUSIONS: P-tau(231) is the strongest predictor of the decline from MCI to AD. IP levels uniquely show longitudinal progression effects. These results suggest the use of CSF biomarkers in secondary prevention trials. |
| DOI | 10.1016/j.neurobiolaging.2007.08.010 |
| Alternate Journal | Neurobiol Aging |
| PubMed ID | 17889968 |
| PubMed Central ID | PMC2774781 |
| Grant List | M01 RR000096-47 / RR / NCRR NIH HHS / United States R01 AG022374 / AG / NIA NIH HHS / United States R01 AG012101-13 / AG / NIA NIH HHS / United States M01 RR000096 / RR / NCRR NIH HHS / United States MO1RR0096 / RR / NCRR NIH HHS / United States R01 AG013616 / AG / NIA NIH HHS / United States P30 AG008051 / AG / NIA NIH HHS / United States R01 AG003051-18 / AG / NIA NIH HHS / United States P30 AG008051-089005 / AG / NIA NIH HHS / United States R01 AG012101 / AG / NIA NIH HHS / United States R01 AG013616-17 / AG / NIA NIH HHS / United States R01 AG003051 / AG / NIA NIH HHS / United States R01 AG012101-15 / AG / NIA NIH HHS / United States P30 AG008051-199005 / AG / NIA NIH HHS / United States AG03051 / AG / NIA NIH HHS / United States AG08051 / AG / NIA NIH HHS / United States R01 AG022374-05 / AG / NIA NIH HHS / United States AG12101 / AG / NIA NIH HHS / United States |
Related Institute:
Brain Health Imaging Institute (BHII)